Cargando…

Salicylic Acid as Ionic Liquid Formulation May Have Enhanced Potency to Treat Some Chronic Skin Diseases

In recent years, numerous studies have shown that conversion of conventional drugs in ionic liquid (IL) formulation could be a successful strategy to improve their physicochemical properties or suggest a new route of administration. We report the synthesis and detailed characterization of eight sali...

Descripción completa

Detalles Bibliográficos
Autores principales: Klebeko, Joanna, Ossowicz-Rupniewska, Paula, Świątek, Ewelina, Szachnowska, Joanna, Janus, Ewa, Taneva, Stefka G., Krachmarova, Elena, Guncheva, Maya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8746858/
https://www.ncbi.nlm.nih.gov/pubmed/35011452
http://dx.doi.org/10.3390/molecules27010216
_version_ 1784630691343892480
author Klebeko, Joanna
Ossowicz-Rupniewska, Paula
Świątek, Ewelina
Szachnowska, Joanna
Janus, Ewa
Taneva, Stefka G.
Krachmarova, Elena
Guncheva, Maya
author_facet Klebeko, Joanna
Ossowicz-Rupniewska, Paula
Świątek, Ewelina
Szachnowska, Joanna
Janus, Ewa
Taneva, Stefka G.
Krachmarova, Elena
Guncheva, Maya
author_sort Klebeko, Joanna
collection PubMed
description In recent years, numerous studies have shown that conversion of conventional drugs in ionic liquid (IL) formulation could be a successful strategy to improve their physicochemical properties or suggest a new route of administration. We report the synthesis and detailed characterization of eight salicylic acid-based ILs (SA-ILs) containing cation non-polar or aromatic amino acid esters. Using in vitro assays, we preliminary evaluated the therapeutic potency of the novel SA-ILs. We observed that conversion of the SA into ionic liquids led to a decrease in its cytotoxicity toward NIH/3T3 murine embryo fibroblasts and human HaCaT keratinocytes. It should be mentioned is that all amino acid alkyl ester salicylates [AAOR][SA] inhibit the production of the proinflammatory cytokine IL-6 in LPS-stimulated keratinocytes. Moreover, keratinocytes, pretreated with [PheOMe][SA] and [PheOPr][SA] seem to be protected from LPS-induced inflammation. Finally, the novel compounds exhibit a similar binding affinity to bovine serum albumin (BSA) as the parent SA, suggesting a similar pharmacokinetic profile. These preliminary results indicate that SA-ILs, especially those with [PheOMe], [PheOPr], and [ValOiPr] cation, have the potential to be further investigated as novel topical agents for chronic skin diseases such as psoriasis and acne vulgaris.
format Online
Article
Text
id pubmed-8746858
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87468582022-01-11 Salicylic Acid as Ionic Liquid Formulation May Have Enhanced Potency to Treat Some Chronic Skin Diseases Klebeko, Joanna Ossowicz-Rupniewska, Paula Świątek, Ewelina Szachnowska, Joanna Janus, Ewa Taneva, Stefka G. Krachmarova, Elena Guncheva, Maya Molecules Article In recent years, numerous studies have shown that conversion of conventional drugs in ionic liquid (IL) formulation could be a successful strategy to improve their physicochemical properties or suggest a new route of administration. We report the synthesis and detailed characterization of eight salicylic acid-based ILs (SA-ILs) containing cation non-polar or aromatic amino acid esters. Using in vitro assays, we preliminary evaluated the therapeutic potency of the novel SA-ILs. We observed that conversion of the SA into ionic liquids led to a decrease in its cytotoxicity toward NIH/3T3 murine embryo fibroblasts and human HaCaT keratinocytes. It should be mentioned is that all amino acid alkyl ester salicylates [AAOR][SA] inhibit the production of the proinflammatory cytokine IL-6 in LPS-stimulated keratinocytes. Moreover, keratinocytes, pretreated with [PheOMe][SA] and [PheOPr][SA] seem to be protected from LPS-induced inflammation. Finally, the novel compounds exhibit a similar binding affinity to bovine serum albumin (BSA) as the parent SA, suggesting a similar pharmacokinetic profile. These preliminary results indicate that SA-ILs, especially those with [PheOMe], [PheOPr], and [ValOiPr] cation, have the potential to be further investigated as novel topical agents for chronic skin diseases such as psoriasis and acne vulgaris. MDPI 2021-12-30 /pmc/articles/PMC8746858/ /pubmed/35011452 http://dx.doi.org/10.3390/molecules27010216 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Klebeko, Joanna
Ossowicz-Rupniewska, Paula
Świątek, Ewelina
Szachnowska, Joanna
Janus, Ewa
Taneva, Stefka G.
Krachmarova, Elena
Guncheva, Maya
Salicylic Acid as Ionic Liquid Formulation May Have Enhanced Potency to Treat Some Chronic Skin Diseases
title Salicylic Acid as Ionic Liquid Formulation May Have Enhanced Potency to Treat Some Chronic Skin Diseases
title_full Salicylic Acid as Ionic Liquid Formulation May Have Enhanced Potency to Treat Some Chronic Skin Diseases
title_fullStr Salicylic Acid as Ionic Liquid Formulation May Have Enhanced Potency to Treat Some Chronic Skin Diseases
title_full_unstemmed Salicylic Acid as Ionic Liquid Formulation May Have Enhanced Potency to Treat Some Chronic Skin Diseases
title_short Salicylic Acid as Ionic Liquid Formulation May Have Enhanced Potency to Treat Some Chronic Skin Diseases
title_sort salicylic acid as ionic liquid formulation may have enhanced potency to treat some chronic skin diseases
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8746858/
https://www.ncbi.nlm.nih.gov/pubmed/35011452
http://dx.doi.org/10.3390/molecules27010216
work_keys_str_mv AT klebekojoanna salicylicacidasionicliquidformulationmayhaveenhancedpotencytotreatsomechronicskindiseases
AT ossowiczrupniewskapaula salicylicacidasionicliquidformulationmayhaveenhancedpotencytotreatsomechronicskindiseases
AT swiatekewelina salicylicacidasionicliquidformulationmayhaveenhancedpotencytotreatsomechronicskindiseases
AT szachnowskajoanna salicylicacidasionicliquidformulationmayhaveenhancedpotencytotreatsomechronicskindiseases
AT janusewa salicylicacidasionicliquidformulationmayhaveenhancedpotencytotreatsomechronicskindiseases
AT tanevastefkag salicylicacidasionicliquidformulationmayhaveenhancedpotencytotreatsomechronicskindiseases
AT krachmarovaelena salicylicacidasionicliquidformulationmayhaveenhancedpotencytotreatsomechronicskindiseases
AT gunchevamaya salicylicacidasionicliquidformulationmayhaveenhancedpotencytotreatsomechronicskindiseases